Table 2.
HIV testing rate and HIV case finding during phase 1 and phase 3 by study site in outpatient departments in eight health facilities, PITC study, Rwanda 2009-2010
| Phase 1 | Phase 3 | Differences between phases 3 and 1 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study site | N | HIV testing rate n | HIV testing rate % | HIV+ n | HIV+ % (of all tested) | HIV+ % (of all eligible) | N | HIV testing rate n | HIV testing rate % | HIV+ n | HIV+ % (of all tested) | HIV+ % (of all eligible) | Difference in testing rate | Difference in HIV case finding |
| A | B | C = B/A | D | E = D/B | F = D/A | G | H | I = H/G | J | K = J/H | L = J/G | M = I - C | N = L - F | |
| Rwaza | 2,270 | 615 | 27.1 % | 10 | 1.6 % | 0.44 % | 3,654 | 1,255 | 34.3 % | 3 | 0.24 % | 0.08 % | 7.3 % | -0.36 % |
| Kinyinya | 2,584 | 34 | 1.3 % | 6 | 17.6 % | 0.23 % | 3,488 | 311 | 8.9 % | 19 | 6.1 % | 0.54 % | 7.6 % | 0.31 % |
| Ruhengeri | 3,829 | 195 | 5.1 % | 8 | 4.1 % | 0.21 % | 5,259 | 612 | 11.6 % | 11 | 1.8 % | 0.21 % | 6.5 % | 0.00 % |
| Muhoza | 10,745 | 50 | 0.5 % | 6 | 12.0 % | 0.06 % | 8,147 | 1,682 | 20.6 % | 47 | 2.8 % | 0.58 % | 20.2 % | 0.52 % |
| Kibagabaga | 2,131 | 313 | 14.7 % | 30 | 9.6 % | 1.41 % | 3,465 | 240 | 6.9 % | 11 | 4.6 % | 0.32 % | -7.8 % | -1.09 % |
| Kimironko | 4,808 | 27 | 0.6 % | 7 | 25.9 % | 0.15 % | 5,851 | 965 | 16.5 % | 45 | 4.7 % | 0.77 % | 15.9 % | 0.62 % |
| Total | 26,367 | 1,234 | 4.7 % | 67 | 5.4 % | 0.25 % | 29,864 | 5,065 | 17.0 % | 136 | 2.7 % | 0.46 % | 12.3 % | 0.21 % |
| Gasiza (c) | 2,959 | 41 | 1.4 % | 4 | 9.8 % | 0.14 % | 2,511 | 22 | 0.9 % | 4 | 18.2 % | 0.16 % | -0.5 % | 0.02 % |
| Kabuye (c) | 1,878 | 201 | 10.7 % | 5 | 2.5 % | 0.27 % | 2,137 | 605 | 28.3 % | 13 | 2.1 % | 0.61 % | 17.6 % | 0.34 % |
| Total | 4,837 | 242 | 5.0 % | 9 | 3.7 % | 0.19 % | 4,648 | 627 | 13.5 % | 17 | 2.7 % | 0.37 % | 8.5 % | 0.18 % |
HIV + = HIV positive individuals. (c) Control site